A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial): Commentary

Tom Huizinga*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Number of pages1
JournalInternational Journal of Advances in Rheumatology
Volume9
Issue number2
StatePublished - Dec 1 2011

ASJC Scopus subject areas

  • Rheumatology

Cite this